{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:05:25Z","timestamp":1791273925691,"version":"4.1.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n in vitro<\/jats:named-content>\n activities of ceftaroline and comparative agents were determined for a collection of the most frequently isolated bacterial pathogens from hospital-associated patients across Canada in 2009 as part of the ongoing CANWARD surveillance study. In total, 4,546 isolates from 15 sentinel Canadian hospital laboratories were tested using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Compared with other cephalosporins, including ceftobiprole, cefepime, and ceftriaxone, ceftaroline exhibited the greatest potency against methicillin-susceptible\n Staphylococcus aureus<\/jats:named-content>\n (MSSA), with a MIC\n 90<\/jats:sub>\n of 0.25 \u03bcg\/ml. Ceftaroline also demonstrated greater potency than ceftobiprole against community-associated methicillin-resistant\n S. aureus<\/jats:named-content>\n (MRSA) (MIC\n 90<\/jats:sub>\n , 0.5 \u03bcg\/ml) and health care-associated MRSA (MIC\n 90<\/jats:sub>\n , 1 \u03bcg\/ml) and was at least 4-fold more active than other cephalosporins against\n Staphylococcus epidermidis<\/jats:named-content>\n ; all isolates of MSSA and MRSA tested were susceptible to ceftaroline (MIC, \u22641 \u03bcg\/ml). Against streptococci, including\n Streptococcus pneumoniae<\/jats:named-content>\n , ceftaroline MICs (MIC\n 90<\/jats:sub>\n , \u22640.03 \u03bcg\/ml) were comparable to those of ceftobiprole; however, against penicillin-nonsusceptible, macrolide-nonsusceptible, and multidrug-nonsusceptible isolates of\n S. pneumoniae<\/jats:named-content>\n , ceftaroline demonstrated 2- to 4-fold and 4- to 16-fold more potent activities than those of ceftobiprole and ceftriaxone, respectively. All isolates of\n S. pneumoniae<\/jats:named-content>\n tested were susceptible to ceftaroline (MIC, \u22640.25 \u03bcg\/ml). Among Gram-negative isolates, ceftaroline demonstrated potent activity (MIC\n 90<\/jats:sub>\n , \u22640.5 \u03bcg\/ml) against\n Escherichia coli<\/jats:named-content>\n (92.2% of isolates were susceptible),\n Klebsiella pneumoniae<\/jats:named-content>\n (94.1% of isolates were susceptible),\n Proteus mirabilis<\/jats:named-content>\n (97.7% of isolates were susceptible), and\n Haemophilus influenzae<\/jats:named-content>\n (100% of isolates were susceptible). Ceftaroline demonstrated less potent activity (MIC\n 90<\/jats:sub>\n , \u22654 \u03bcg\/ml) against\n Enterobacter<\/jats:named-content>\n spp.,\n Acinetobacter baumannii<\/jats:named-content>\n ,\n Pseudomonas aeruginosa<\/jats:named-content>\n ,\n Klebsiella oxytoca<\/jats:named-content>\n ,\n Serratia marcescens<\/jats:named-content>\n , and\n Stenotrophomonas maltophilia<\/jats:named-content>\n . Overall, ceftaroline demonstrated potent\n in vitro<\/jats:named-content>\n activity against a recent collection of the most frequently encountered Gram-positive and Gram-negative isolates from patients attending hospitals across Canada in 2009.\n <\/jats:p>","DOI":"10.1128\/aac.01787-10","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T18:53:46Z","timestamp":1300215226000},"page":"2837-2846","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009"],"prefix":"10.1128","volume":"55","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"Diagnostic Services of Manitoba\/Department of Clinical Microbiology, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[{"name":"Diagnostic Services of Manitoba\/Department of Clinical Microbiology, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"DeCorby","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R. S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[{"name":"Diagnostic Services of Manitoba\/Department of Clinical Microbiology, St. Boniface General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[{"name":"Diagnostic Services of Manitoba\/Department of Clinical Microbiology, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01176-07"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.03.006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh391"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01021-08"},{"key":"e_1_3_2_7_2","first-page":"459","article-title":"Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production","volume":"173","author":"Caroff N.","year":"1999","unstructured":"CaroffN. EspazeE. BerardI. RichetH. ReynaudA.. 1999. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol. Lett. 173:459\u2013465.","journal-title":"FEMS Microbiol. Lett"},{"key":"e_1_3_2_8_2","unstructured":"Centers for Disease Control and Prevention Streptococcus Laboratory. 2010. PCR deduction of pneumococcal serotypes. CDC Atlanta GA. http:\/\/www.cdc.gov\/ncidod\/biotech\/strep\/pcr.htm."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01788-09"},{"key":"e_1_3_2_10_2","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20148th edition. M07-A8. CLSI Wayne PA."},{"key":"e_1_3_2_11_2","unstructured":"Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. M100-S20. CLSI Wayne PA."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/655827"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00081-09"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-07"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000253059.84602.c3"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00149-08"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/754249"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01797-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.12.6147-6149.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1204-1214.2004"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp493"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm150"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq161"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690097"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.1.124-131.2006"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp231"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3501-3512.2005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01516-09"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.879"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969070-00003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01787-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01787-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:33:06Z","timestamp":1645486386000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01787-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1128\/AAC.01787-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01787-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"2010-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}